The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans

Behavioural Pharmacology

Volumn 9, Issue 7, 1998, Pages 587-598

  Collins, E D ^a,b   Ward, A S ^a   McDowell, D M ^a   Foltin, R W ^a   Fischman, M W ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

Author keywords

Cardiovascular effects; Cocaine; Humans; Memantine; NMDA antagonist; Self administration; Subjective effects

Indexed keywords

COCAINE; MEMANTINE;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFECT; DRUG SELF ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PSYCHOMOTOR ACTIVITY; RATING SCALE; REINFORCEMENT;

EID: 0031797681     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199811000-00014     Document Type: Article

References (66)

1. Ambrozi L, Danielezyk W (1988). Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a double-blind study. Pharmacopsychiatry 21:144-146.
2. Balster RL, Chait LD (1978). The effects of phenycyclidine on amphetamine stereotypy in rats. Eur J Pharmacol 48:445-450.
3. Bisaga A, Gianelli P, Popik P (1997). Opiate withdrawal with dextromethorphan. Am J Psychiatry 154:584.
4. De Montis MG, Devoto P, Meloni D, Gambarana C, Giorgi G, Tagliamonte A (1992). NMDA receptor inhibition prevents tolerance to cocaine. Pharmacol Biochem Bchar 42:179-182.
5. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A (1995). Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol 6:562-567.
6. Druhan JP, Jakob A, Stewart J (1993). The development of behavioral sensitization to apomorphine is blocked by MK-801. Eur J Pharmacol 243:73-77.
7. Dudish SA, Hatsukami DK (1996). Gender differences in crack users who are research volunteers. Drug Alcohol Depend 42:55-63.
8. Elliott K, Hynansky A, Inturrisi CE (1994a). Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 59:361-368.
9. Elliot K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE (1994b). The NMDA receptor agonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine hut not to kappa opioids. Pain 56:69-75.
10. Elliot KJ, Brodsky M, Hyanansky A, Foley KM, Inturrisi CE (1995a). Dextromethorphan shows efficiacy in experimental pain (nociception) and opioid tolerance. Neurology 45:S66-S68.
11. Elliot K, Kest B, Man A, Kao B, Inturrisi CE (1995b). N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 13:347-356.
12. Evans SM, Haney M, Fischman MW, Foltin RW (1998). Limited sex differences in response to hinge smoked cocaine use in humans. Neuropsychopharmacology (In press).
13. Fischman MW (1984). The behavioural pharmacology of cocaine in humans. Washington, DC: US Printing Office.
14. Fischman MW, Foltin RW, Brady JV (1988). Human drug taking under controlled laboratory conditions. Washington, DC: US Governament Printing Office.
15. Fischman MW, Foltin RW, Nestadt G, Pearlson GD (1990). Effects of desipramine maintenance on cocaine self-administration by humans. J Pharm Exp Ther 253:760-770.
16. Foltin RW, Fischman MW (1991). Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharm Exp Ther 257:247-261.
17. Foltin RW, Fischman MW (1996). Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharm Exp Ther 278:1153-1164.
18. French ED, Mura A, Wang T (1993). MK-801, phenylcyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13:108-116.
19. Gortelmeyer R, Erbler H (1992). Memantine in the treatment of mild to moderate dementia syndrome. Arzneimittelforschung 42:904-913.
20. Gortelmeyer R, Pantev M, Parsons CG, Quack G (1993). The treatment of dementia syndrome with akatinol memantine, a modulator of the glutaminergic system. In: Spektrum der Neurorehabilitation. von Wild K (editor). Munchen: W. Zuckschwerdt. pp. 50-56.
21. Haney M, Foltin RW, Fischman MW (1998). Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (In press).
22. Haracz JL, Belanger SA, MacDonnall JS, Sircar R (1995). Anatagonist of N-methyl-D-aspartate receptors partially prevent the development of cocaine sensitization. Life Sci 57:2347-2357.
23. Herman BH, Vocci F, Bridge P (1995). The effects of NMDA receptor agonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 13:269-293.
24. Holmberg S, Serzysko W, Varnauskas E (1971). Coronary circulation during heavy exercise in control subjects and patients wih coronary heart disease. Acta Med Scand 190:465-480.
25. Ida I, Asami T, Kuribara H (1995). Inhibition of cocaine sensitization by MK-801, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist: evaluation by ambulatory activity in mice. Jpn J Pharmacol 69:83-90.
26. Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, Cook CCE (1989). Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting) or smoking. Drug Metab Dispos 17:153-159.
27. Jenkins AJ, Cone EJ (1998). Pharmacokineticcs: drug absorption, disrtibution, and elimination. In: Drug abuse handbook. Karch SB (editor). New York: CRC Press, pp. 184-187.
28. Kalivas PW (1995). Can EAA transmission play a ubiquitous role in drug-induced neural plasticity? [Commentary]. Behav Pharmacol 6:452-454.
29. Karler R, Calder LD (1992). Excitatory amino acids and the actions of cocaine. Brain Res 582:143-146.
30. Karler R, Calder LD, Chaudhry IA, Turkanis SA (1990). Blockade of reverse tolerance' to cocaine and amphetamine by MK-801. Life Sci 45:599-606.
31. Karler R, Calder LD, Turkanis SA (1991). DNOX blockade of amphetamine behavioural sensitization. Brain Res 552:295-300.
32. Karler R, Chaudhry IA, Calder LD, Turkanis SA (1990). Amphetamine behavioural sensitization and excitatory amino acids. Brain Res 537:76-82.
33. Kitamura K, Jorgensen CR, Gobel FL, Taylor HL, Wang Y (1972). Hemodynamic correlates of myocardial oxygen consumption during upright exercise. J Appl Physiol 32:516-522.
34. Kornhuber J, Weller M, Schoppmeyer K, Reiderer P (1994). Amantidine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104.
35. Koyuncuoglu H (1995). The combination of tizanidine markedly improves treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharm Ther 33:13-19.
36. Koyuncuoglu H, Saydam B (1990). The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharm Ther Toxicol 147-152.
37. Little RJA, Rubin DB (1987). Statistical analysis with missing data. New York: John Wiley.
38. Lukas SE, Sholar M, Lundahl LH, Lamas X, Kouri E, Wines JD et al. (1996). Sex differences in plasma cocaine levels and subjective effects after acute cocaine administrations in human volunteers. Psychopharmacology 125:346-354.
39. McGinty JF (1995). Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence. Drug Alcohol Depend 37:91-94.
40. McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982). An automated version of the Digit Symbol Substitution Test (DSST). Behav Res Meth Instrument 14:463-466.
41. Miller DW, Abercrombie ED (1996). Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40:57-62.
42. National Institute of Drug Abuse (1995). Epidemiologic trends in drug abuse. In: Proceedings of the Community Epidemiology Work Group. Rockville, MA: US Department of Health and Human Services.
43. Pantev M, Ritter R, Gortelmeyer R (1993). Clinical and behavioural evaluation of long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol Psychiatr 6:103-117.
44. Pap A, Bradberry CW (1995). Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens. J Pharm Exp Ther 274:127-133.
45. Pulvirenti L, Maldonado-Lopez R, Koob GF (1992). NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-adminstration in the rat. Brain Res 594:327-330.
46. Pulvirenti L, Swerdlow NR, Koob GF (1991). Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharm Biochem Behav 40:841-845.
47. Rabey JM, Nissipeanu P, Korczyn AD (1992). Efficacy of meniantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 4:277-282.
48. Ranaldi R, Bauco P, Wise RA (1997). Synergistic effects of cocaine and dizocilpine (MK-801) on brain stimulation reward. Brain Res 760:231-237.
49. Ranaldi R, French E, Roberts DC (1996). Systemic pretreatment with MK-801 (dizocilpine) increases breaking points for self-adminstration of cocaine on progressive-ratio schedule in rats. Psychopharmacol 128:83-88.
50. Reiderer P, Lang KW, Kornhuber J, Danielczyk W (1991). Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338:1022-1023.
51. Rosen MI, MacMahon TJ, Woods SW, Pearsall HR, Kosten TR (1996). A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur J Pharm 307:251-257.
52. Rubin DB, Schenker N (1991). Multiple imputation in healthcare databases: an overview and some applications. Stat Med 10:585-598.
53. Schenk S, Valadez A, McNamara C, House DT, Higley D, Bankson MG (1993a). Development and expression of senstization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacol 111:332-338.
54. Schenk S, Valadez A, Worley CM, McNamara C (1993b). Blockade of the aquisition of cocaine self-administration by the NMDA antagonist MK-801 (dizocilpine). Behav Pharmacol 4:652-659.
55. Stephens DN (1995). A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav Pharmacol 6:425-426.
56. Stewart J, Druhan JP (1993). Development of both conditioning and sensitization of the behavioural activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacol 110:125-132.
57. Tallarida RJ, Murray RB (1981). Manual of pharmacological calculations with computer programs. New York: Springer.
58. Trujillo KA (1995). Effects of noncompetitive N-methyl-D-asparate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacol 13:301-307.
59. Trujillo KA, Akil H (1991). Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87.
60. Weseman W, Sturm G, Funfgeld HW (1980). Distribution of metabolism of the potential anti-Parkinson drug memantine in the human. J Neural Transm Suppl 143-148.
61. Wise RA (1984). Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr 50:15-33.
62. Wise RA, Bozarth MA (1984). Brain reward circuitry: four circuit elements 'wired' in apparent series. Brain Res Bull 12:203-208.
63. Wolf MH, Dahlin SL, Hu XT, Xue CJ, White K (1995). Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioural sensitization to amphetamine: comparison with N-methyl-D-aspartate antagonists. Neuroscience 69:417-434.
64. Wolf MH, Jeziorski M (1993). Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioural sensitization. Brain Res 613:291-294.
65. Wolf MH, Khansa MR (1991). Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 562:164-168.
66. Wolf ME, Xue CJ, While FJ, Dahlin SL (1994). MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens. Brain Res 666:223-231.